Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-332-3410
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$12.93 million
Profitability
Miscellaneous
Employees63
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions
What is Mirati Therapeutics' stock symbol?
Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."
How were Mirati Therapeutics' earnings last quarter?
Mirati Therapeutics Inc (NASDAQ:MRTX) issued its earnings results on Monday, August, 5th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.19) by $0.07. The biotechnology company had revenue of $0.58 million for the quarter. View Mirati Therapeutics' Earnings History.
When is Mirati Therapeutics' next earnings date?
What price target have analysts set for MRTX?
16 equities research analysts have issued 12 month price objectives for Mirati Therapeutics' stock. Their forecasts range from $81.00 to $130.00. On average, they expect Mirati Therapeutics' stock price to reach $106.07 in the next year. This suggests a possible upside of 37.1% from the stock's current price. View Analyst Price Targets for Mirati Therapeutics.
What is the consensus analysts' recommendation for Mirati Therapeutics?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mirati Therapeutics.
What are Wall Street analysts saying about Mirati Therapeutics stock?
Here are some recent quotes from research analysts about Mirati Therapeutics stock:
- 1. According to Zacks Investment Research, "Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. " (10/10/2019)
- 2. HC Wainwright analysts commented, "Our $117 price target is based on a sum-of-the-parts analysis determined by probability adjusted revenue forecasts for sitravatinib and MRTX849. We use the net present value of our revenue forecast through 2027, apply a 50% probability of success (POS) for sitravatinib in combination with checkpoint inhibitors, a 45% POS for sitravatinib monotherapy, 20% POS for MRTX849, and our YE19 fully diluted net cash estimate of $8.00/share to arrive at our price target." (8/6/2019)
- 3. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating and 12-month price target of $66 on MRTX. This evening, ASCO abstracts for oral and poster presentations were published online that included Amgen’s (N, covered by A. Young) first clinical data from its KRASi AMG510, which is a potential read to Mirati’s MRTX849. Overall, early AMG510 data seem to be still preliminary, and full data at ASCO (6/3) will remain a key investor focus to assess single-agent vs. combo strategy, in our view. We have provided more detailed color on pgs. 2-5. Amgen’s KRASi AMG510 early data in abstract still preliminary. In the dose- escalation stage, AMG510 reported 1 confirmed PR (11% ORR) from 9 evaluable patients (of total 22 pts.)." (5/16/2019)
Has Mirati Therapeutics been receiving favorable news coverage?
Press coverage about MRTX stock has trended negative this week, according to InfoTrie. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mirati Therapeutics earned a coverage optimism score of -2.8 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Mirati Therapeutics.
Are investors shorting Mirati Therapeutics?
Mirati Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 5,330,000 shares, an increase of 9.9% from the August 30th total of 4,850,000 shares. Based on an average trading volume of 526,900 shares, the days-to-cover ratio is presently 10.1 days. Approximately 13.8% of the company's stock are sold short. View Mirati Therapeutics' Current Options Chain.
Who are some of Mirati Therapeutics' key competitors?
Some companies that are related to Mirati Therapeutics include BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Perrigo (PRGO), Catalent (CTLT), SAGE Therapeutics (SAGE), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ) and Dr.Reddy's Laboratories (RDY).
What other stocks do shareholders of Mirati Therapeutics own?
Who are Mirati Therapeutics' key executives?
Mirati Therapeutics' management team includes the folowing people:
- Dr. Charles M. Baum, Pres, CEO & Director (Age 61)
- Dr. James Christensen, Chief Scientific Officer & Exec. VP (Age 51)
- Dr. Isan Chen, Exec. VP and Chief Medical & Devel. Officer (Age 57)
- Mr. Jamie A. Donadio, Sr. VP & CFO (Age 44)
- Temre Johnson, Director of Investor Relations & Corp. Communications
How do I buy shares of Mirati Therapeutics?
Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Mirati Therapeutics' stock price today?
One share of MRTX stock can currently be purchased for approximately $77.37.
How big of a company is Mirati Therapeutics?
Mirati Therapeutics has a market capitalization of $3.04 billion and generates $12.93 million in revenue each year. The biotechnology company earns $-98,420,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Mirati Therapeutics employs 63 workers across the globe.View Additional Information About Mirati Therapeutics.
What is Mirati Therapeutics' official website?
How can I contact Mirati Therapeutics?
Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]
MarketBeat Community Rating for Mirati Therapeutics (NASDAQ MRTX)
MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe MRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
